Loading organizations...

§ Private Profile · San Francisco, CA, USA
Mission Bio is a technology company.
Mission Bio has raised $94.0M across 4 funding rounds.
Key people at Mission Bio.
Mission Bio has raised $94.0M in total across 4 funding rounds.
Mission Bio offers the Tapestri Platform, a unique single-cell multi-omics solution. This technology enables simultaneous detection of genotype and phenotype from individual cells, providing precise identification of cellular heterogeneity. It gives researchers an unparalleled view into disease progression and treatment response.
Charlie Silver co-founded Mission Bio, originating from University of California, San Francisco research in 2014. An engineer, Silver was motivated by a drive to "see deeper" into biological systems. This insight, combined with a commitment to impact human health through advanced technology, led to developing a platform for high-resolution cellular understanding.
The platform assists researchers in oncology, encompassing blood cancers, solid tumors, and genome editing validation. Pharmaceutical companies leverage its capabilities for drug development and clinical research. Mission Bio's vision is to empower customers with critical data to deepen understanding and ultimately eradicate cancer, bringing significant patient benefits.
Mission Bio has raised $94.0M in total across 4 funding rounds.
Mission Bio's investors include Robert Ghenchev, Endeavor Venture Funds, InterWest, Robert Garland, Polaris Partners, Agilent Technologies, Cota Capital, Mayfield, Soleus Capital, Lam Capital, Keiretsu Forum, Life Science Angels.
Key people at Mission Bio.
Mission Bio has raised $94.0M across 4 funding rounds. Most recently, it raised $25.0M Series C in July 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2020 | $25M Series C | Robert Ghenchev | Endeavor Venture Funds, InterWest, Robert Garland, Polaris Partners, Agilent Technologies, Cota Capital, Mayfield, Soleus Capital | Announced |
| Dec 13, 2018 | $30M Series B | — | Agilent Technologies, Cota Capital, LAM Capital, Mayfield | Announced |
| Jul 1, 2018 | $29M Series B | — | — | Announced |
| Oct 17, 2017 | $10M Series A | Mayfield | Keiretsu Forum, Life Science Angels, Stanford, Tech Coast Angels | Announced |
Mission Bio is a life‑sciences technology company that develops the Tapestri single‑cell multi‑omics platform to measure DNA variants (SNVs and CNVs) and proteins from the same individual cells to advance precision medicine, especially in oncology and cell & gene therapy applications.[5][2]
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech & Life‑Sciences Landscape
Quick Take & Future Outlook
Quick take: Mission Bio occupies a differentiated niche by delivering targeted single‑cell DNA plus protein multi‑omics and bundled assay services that address a pressing analytical bottleneck for oncology and cell & gene therapy developers, and its future trajectory will depend on scaling, regulatory acceptance, and continued demonstration of clinical and manufacturing value.[5][6]
Sources used: Mission Bio company site and team pages, product and application pages, press/CGT survey, and industry profiles summarizing company history and capabilities.[1][5][6][2]